N
0.099
0.00 (0.00%)
| Previous Close | 0.099 |
| Open | 0.099 |
| Volume | 34,049 |
| Avg. Volume (3M) | 166,339 |
| Market Cap | 28,931,564 |
| Price / Book | 5.26 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -149.07% |
| Operating Margin (TTM) | -197.16% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | -55.40% |
| Current Ratio (MRQ) | 3.83 |
| Levered Free Cash Flow (TTM) | 1.09 M |
| Return on Assets (TTM) | -34.01% |
| Return on Equity (TTM) | -49.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | NOXOPHARM FPO [NOX] | - | - |
AIStockmoo Score
-0.6
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 35.03% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |